Health Catalyst Beat Q2 — Then Cut Its Own Full-Year Guidance by Nearly 6%. The Stock Fell Sharply and Only Partly Recovered

Health Catalyst reported second-quarter 2026 revenue of $70.49 million on August 6, 2026, beating the $69.06 million analyst estimate, even though sales fell 12.7% year over year — a beat against a shrinking base rather than a beat driven by growth. Adjusted EBITDA of $9.92 million beat the $9.43 million estimate, and adjusted EPS of $0.04 beat the $0.03 estimate.

The guidance that followed overshadowed the current-quarter beat. Third-quarter revenue guidance of $55.5 million landed about 10.7% below what analysts had modeled, and the company cut its own full-year revenue guidance to $247.5 million at the midpoint, down from a prior $262.5 million — a reduction of roughly 5.7%. A company cutting its own full-year number this soon after beating the quarter just reported is a stronger negative signal than a simple miss would be: management is telling investors directly that the rest of the year looks worse than it did three months ago, based on information only the company has.

Shares fell sharply in the immediate reaction to the report before recovering part of the initial drop — a pattern typical of a thinly-traded stock in the first minutes after unexpected news, when a wide bid-ask spread and few active market makers can cause an initial move to overshoot before the market settles on a more considered price. The scale of the settled decline was still severe, reflecting that investors read the guidance cut, not the quarterly beat, as the material information in the release.